Evolysse
Next-generation OXIFREE hybrid HA filler technology
About This Treatment
Evolysse is a next-generation hyaluronic acid filler developed by Across Pharmaceuticals in Switzerland. The proprietary OXIFREE cross-linking technology minimizes oxidative reactions, providing superior stability and longevity. Delivers dynamic facial volumization while maintaining natural facial expressions and movement.
Mechanism of Action
OXIFREE cross-linking technology significantly reduces oxidative degradation inherent in conventional cross-linking methods. The hybrid polymer network maintains elasticity post-injection while providing long-term structural stability and integration with native tissues.
Indications
Expected Results
Immediate volumization upon injection with full integration within 4-6 weeks. Results typically persist for 12-18 months. Maintains natural appearance and facial mobility throughout duration.
Clinical Evidence
Risks & Side Effects
Temporary swelling, erythema, and bruising at injection sites are common. Rare allergic reactions and granuloma formation have been documented. Intravascular injection risk is minimal with proper technique.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition